Equities

Galectin Therapeutics Inc

Galectin Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.23
  • Today's Change0.09 / 2.87%
  • Shares traded148.56k
  • 1 Year change+93.41%
  • Beta0.6889
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments261940
Total Receivables, Net------
Total Inventory------
Prepaid expenses2.051.962.17
Other current assets, total------
Total current assets282142
Property, plant & equipment, net0.050.090.01
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets0.440.65--
Total assets282142
LIABILITIES
Accounts payable6.433.891.81
Accrued expenses9.189.067.16
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total0.060.060.07
Total current liabilities16139.03
Total long term debt724029
Total debt724029
Deferred income tax------
Minority interest------
Other liabilities, total1.020.641.13
Total liabilities885339
SHAREHOLDERS EQUITY
Common stock0.060.060.06
Additional paid-in capital292275271
Retained earnings (accumulated deficit)(354)(310)(271)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity(60)(32)2.62
Total liabilities & shareholders' equity282142
Total common shares outstanding625959
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.